Testing for HRR mutations can uncover a distinct patient population.

Discover the patients who are most at risk.

Depending on tumor type, up to 33% of patients with cancer have a mutation in HRR genes, like BRCA1/2 and ATMwhich may be associated with an increased risk of developing certain cancer types.1-6

HRRm Prostate Cancer

Explore

BRCA1/2m Pancreatic Cancer

Explore

HRR mutations may also result in a distinct cancer that may progress more quickly and may be associated with a poorer prognosis, primarily in prostate cancer.7,8

Testing for HRR gene mutations in appropriate patients may provide additional information about prognosis and inform familial risk.9-11

ATM=ataxia-telangiesctasia mutated; BRCA1/2m=BRCA1/2-mutated; HRR=homologous recombination repair; HRRm=HRR-mutated.

REFERENCES: 1. Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types [published online July 23, 2018]. JCO Precis Oncol. 2018;2018. doi:10.1200/PO.17.00286. 2. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697-1708. 3. Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol. 2018;10:1-18. 4. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38(8):873-875. 5. Bakker JL, de Winter JP. A role for ATM in hereditary pancreatic cancer. Cancer Discov. 2012;2(1):14-15. 6. Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making [published online May 31, 2017]. JCO Precis Oncol. 2017; doi:10.1200/PO.17.00029. 7. Knijnenburg TA, Wang L, Zimmermann MT, et al. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23(1):239-254. 8. Na R, Zheng SL, Han M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017;71(5):740-747. 9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed April 17, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. 10. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma V.2.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed April 9, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. 11. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V.2.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed March 26, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.